OCUGEN, INC. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
OCUGEN, INC. (OCGN) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of 0.20% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-04
- OCUGEN, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was 0.20%, a 33.33% decline from fiscal 2024.
- OCUGEN, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 0.30%.
- OCUGEN, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -1.60%.
- OCUGEN, INC. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -1.60%, a 1700.00% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.20% 10-K · filed 2026-03-04 | |
| 2024-12-31 | 0.30% 10-K · filed 2026-03-04 | -2.00% 10-K · filed 2025-03-05 |
| 2023-12-31 | -1.60% 10-K · filed 2025-03-05 | |
| 2022-12-31 | -1.60% 10-K · filed 2024-04-16 | 1.70% 10-K · filed 2023-02-28 |
| 2021-12-31 | 0.10% 10-K · filed 2023-02-28 | 0.00% 10-K · filed 2022-02-28 |
| 2020-12-31 | 1.10% 10-K · filed 2022-02-28 | |
| 2019-12-31 | 2.90% 10-K · filed 2022-02-28 | |
| 2018-12-31 | 0.00% 10-K · filed 2020-03-27 | -0.40% 10-K · filed 2019-03-22 |
| 2017-12-31 | 1.50% 10-K · filed 2019-03-22 | |
| 2016-12-31 | 0.90% 10-K · filed 2018-03-15 | |
| 2015-12-31 | -1.20% 10-K · filed 2017-03-16 | -1.10% 10-K · filed 2016-03-10 |
| 2014-12-31 | 0.00% 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |